Shire fends off AbbVie takeover bid


Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. AbbVie made three efforts at proposing a deal, with the largest worth around $27 billion (£16 billion) in a combination of cash and shares.

Shire’s board rejected the first two proposals outright, but met with AbbVie to clarify the terms of the third proposal, before once again rejecting it unanimously. Shire claimed in a statement that the offer ‘fundamentally undervalued Shire and its prospects as a leader in rare diseases and speciality markets’. Shire’s biggest selling product is Attention Deficit Hyperactivity Disorder drug Vyvanse (lisdexamfetamine), but in recent years it has built up a portfolio of treatments for rare diseases.

Shire’s board also expressed concerns about the tax structure of the deal, which would see the new company move its base to the UK – Shire is currently registered in Ireland, after relocating to benefit from reduced tax rates. In a filing with the US Securities and Exchange Commission, AbbVie confirmed that it is no longer in negotiations with Shire. However, that does not preclude further developments – under UK takeover rules, AbbVie now has until 18 July to make a firm offer for Shire, take its proposal direct to shareholders, or withdraw its interest.

This is the latest in a string of attempts to use mergers to escape the US tax regime. Pfizer failed in its bid to buy AstraZeneca, but device specialist Medtronic successfully wooed rival Covidien.


Related Content

Generics firms in three-way takeover battle

1 May 2015 Business

news image

Mylan is chasing Perrigo, while fending off advances from Teva

Generics giant Mylan offers $30 billion for Perrigo

13 April 2015 Business

news image

Mylan makes ambitious takeover offer just weeks after Abbott aquisition closes

Most Read

Chemical linguistics

24 June 2015 Comments

news image

Chemistry is not language, explains Michael Gordin. But the metaphor is useful nonetheless

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...